Nuwellis (NUWE) Competitors

$1.05 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.88 -0.17 (-16.57%)

As of 05/22/2026 07:55 PM Eastern

NUWE vs. VVOS, SINT, TNON, INBS, and XAIR

Should you buy Nuwellis stock or one of its competitors? MarketBeat compares Nuwellis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuwellis include Vivos Therapeutics (VVOS), Sintx Technologies (SINT), Tenon Medical (TNON), Intelligent Bio Solutions (INBS), and Beyond Air (XAIR). These companies are all part of the "medical equipment" industry.

How does Nuwellis compare to Vivos Therapeutics?

Vivos Therapeutics (NASDAQ:VVOS) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Nuwellis has lower revenue, but higher earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.49	-$21.17M	-$2.14	N/A
Nuwellis	$8.27M	0.34	-$17.52M	-$64.02	N/A

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by insiders. Comparatively, 1.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vivos Therapeutics presently has a consensus price target of $2.75, indicating a potential upside of 350.82%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Vivos Therapeutics is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Vivos Therapeutics has a beta of 6.25, indicating that its stock price is 525% more volatile than the broader market. Comparatively, Nuwellis has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

In the previous week, Vivos Therapeutics had 7 more articles in the media than Nuwellis. MarketBeat recorded 7 mentions for Vivos Therapeutics and 0 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.00 beat Vivos Therapeutics' score of -0.17 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Overall Sentiment
Vivos Therapeutics	Neutral
Nuwellis	Neutral

Vivos Therapeutics has a net margin of -127.70% compared to Nuwellis' net margin of -214.90%. Vivos Therapeutics' return on equity of -2,325.64% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Nuwellis	-214.90%	-32,351.83%	-249.08%

Summary

Vivos Therapeutics beats Nuwellis on 13 of the 16 factors compared between the two stocks.

How does Nuwellis compare to Sintx Technologies?

Nuwellis (NASDAQ:NUWE) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Sintx Technologies has a consensus target price of $11.00, suggesting a potential upside of 360.25%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Sintx Technologies is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Sintx Technologies has lower revenue, but higher earnings than Nuwellis. Sintx Technologies is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.34	-$17.52M	-$64.02	N/A
Sintx Technologies	$1.02M	10.12	-$10.36M	-$5.07	N/A

Nuwellis has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

In the previous week, Sintx Technologies had 10 more articles in the media than Nuwellis. MarketBeat recorded 10 mentions for Sintx Technologies and 0 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.00 equaled Sintx Technologies'average media sentiment score.

Company	Overall Sentiment
Nuwellis	Neutral
Sintx Technologies	Neutral

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 1.6% of Nuwellis shares are held by insiders. Comparatively, 4.1% of Sintx Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Nuwellis has a net margin of -214.90% compared to Sintx Technologies' net margin of -1,058.60%. Sintx Technologies' return on equity of -366.49% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Sintx Technologies	-1,058.60%	-366.49%	-115.04%

Summary

Sintx Technologies beats Nuwellis on 12 of the 15 factors compared between the two stocks.

How does Nuwellis compare to Tenon Medical?

Nuwellis (NASDAQ:NUWE) and Tenon Medical (NASDAQ:TNON) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Tenon Medical had 1 more articles in the media than Nuwellis. MarketBeat recorded 1 mentions for Tenon Medical and 0 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.00 equaled Tenon Medical'saverage media sentiment score.

Company	Overall Sentiment
Nuwellis	Neutral
Tenon Medical	Neutral

Nuwellis has a net margin of -214.90% compared to Tenon Medical's net margin of -270.09%. Tenon Medical's return on equity of -907.60% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Tenon Medical	-270.09%	-907.60%	-110.17%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tenon Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 22.7% of Tenon Medical shares are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Comparatively, 0.3% of Tenon Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tenon Medical has lower revenue, but higher earnings than Nuwellis. Tenon Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.34	-$17.52M	-$64.02	N/A
Tenon Medical	$3.94M	2.11	-$12.56M	-$1.29	N/A

Nuwellis has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Tenon Medical has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Summary

Tenon Medical beats Nuwellis on 10 of the 14 factors compared between the two stocks.

How does Nuwellis compare to Intelligent Bio Solutions?

Nuwellis (NASDAQ:NUWE) and Intelligent Bio Solutions (NASDAQ:INBS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intelligent Bio Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuwellis has a net margin of -214.90% compared to Intelligent Bio Solutions' net margin of -296.73%. Intelligent Bio Solutions' return on equity of -176.09% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Intelligent Bio Solutions	-296.73%	-176.09%	-89.71%

Intelligent Bio Solutions has lower revenue, but higher earnings than Nuwellis. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.34	-$17.52M	-$64.02	N/A
Intelligent Bio Solutions	$3.05M	2.01	-$10.57M	-$12.22	N/A

Nuwellis has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Intelligent Bio Solutions has a beta of 4.24, meaning that its share price is 324% more volatile than the broader market.

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are held by institutional investors. 1.6% of Nuwellis shares are held by insiders. Comparatively, 1.3% of Intelligent Bio Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Intelligent Bio Solutions had 1 more articles in the media than Nuwellis. MarketBeat recorded 1 mentions for Intelligent Bio Solutions and 0 mentions for Nuwellis. Intelligent Bio Solutions' average media sentiment score of 1.19 beat Nuwellis' score of 0.00 indicating that Intelligent Bio Solutions is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuwellis	Neutral
Intelligent Bio Solutions	Positive

Summary

Intelligent Bio Solutions beats Nuwellis on 9 of the 13 factors compared between the two stocks.

How does Nuwellis compare to Beyond Air?

Beyond Air (NASDAQ:XAIR) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Nuwellis has a net margin of -214.90% compared to Beyond Air's net margin of -447.75%. Beyond Air's return on equity of -268.82% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beyond Air	-447.75%	-268.82%	-98.49%
Nuwellis	-214.90%	-32,351.83%	-249.08%

31.5% of Beyond Air shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 10.0% of Beyond Air shares are held by company insiders. Comparatively, 1.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Beyond Air currently has a consensus target price of $10.00, suggesting a potential upside of 2,393.77%. Given Beyond Air's stronger consensus rating and higher possible upside, analysts clearly believe Beyond Air is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beyond Air	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuwellis has higher revenue and earnings than Beyond Air. Beyond Air is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beyond Air	$3.70M	1.43	-$46.62M	-$5.43	N/A
Nuwellis	$8.27M	0.34	-$17.52M	-$64.02	N/A

In the previous week, Beyond Air's average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score.

Company	Overall Sentiment
Beyond Air	Neutral
Nuwellis	Neutral

Beyond Air has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Summary

Beyond Air beats Nuwellis on 10 of the 14 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUWE vs. The Competition

Export

Metric	Nuwellis	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.81M	$7.10B	$6.46B	$12.34B
Dividend Yield	N/A	1.68%	2.76%	5.28%
P/E Ratio	-0.02	47.45	21.00	25.66
Price / Sales	0.34	73.72	558.19	86.31
Price / Cash	N/A	24.91	43.49	56.67
Price / Book	1.06	6.53	10.40	7.14
Net Income	-$17.52M	$158.81M	$3.57B	$335.98M
7 Day Performance	7.38%	3.61%	6.40%	4.11%
1 Month Performance	-11.02%	0.74%	3.55%	2.52%
1 Year Performance	-97.31%	3.17%	34.13%	35.04%

Nuwellis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUWE Nuwellis	0.1554 of 5 stars	$1.05 flat	N/A	-97.3%	$2.81M	$8.27M	N/A	70	Gap Down High Trading Volume
VVOS Vivos Therapeutics	2.9091 of 5 stars	$0.72 -1.4%	$2.58 +260.6%	-73.2%	$9.82M	$17.44M	N/A	160	Earnings Report
SINT Sintx Technologies	2.6558 of 5 stars	$2.38 -0.8%	$11.00 +362.2%	-11.2%	$9.81M	$1.02M	N/A	40	Gap Down
TNON Tenon Medical	0.6895 of 5 stars	$0.72 -11.5%	N/A	-35.4%	$8.13M	$3.94M	N/A	8	Gap Down
INBS Intelligent Bio Solutions	0.8776 of 5 stars	$3.99 +25.5%	N/A	-81.8%	$7.98M	$3.58M	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUWE) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuwellis (NUWE) Competitors

NUWE vs. VVOS, SINT, TNON, INBS, and XAIR

How does Nuwellis compare to Vivos Therapeutics?

Summary

How does Nuwellis compare to Sintx Technologies?

Summary

How does Nuwellis compare to Tenon Medical?

Summary

How does Nuwellis compare to Intelligent Bio Solutions?

Summary

How does Nuwellis compare to Beyond Air?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuwellis (NUWE) Competitors

NUWE vs. VVOS, SINT, TNON, INBS, and XAIR

How does Nuwellis compare to Vivos Therapeutics?

Which has preferable valuation & earnings, VVOS or NUWE?

Do insiders & institutionals have more ownership in VVOS or NUWE?

Do analysts rate VVOS or NUWE?

Which has more volatility & risk, VVOS or NUWE?

Does the media refer more to VVOS or NUWE?

Is VVOS or NUWE more profitable?

Summary

How does Nuwellis compare to Sintx Technologies?

Do analysts rate NUWE or SINT?

Which has higher valuation and earnings, NUWE or SINT?

Which has more risk and volatility, NUWE or SINT?

Does the media favor NUWE or SINT?

Do insiders and institutionals have more ownership in NUWE or SINT?

Is NUWE or SINT more profitable?

Summary

How does Nuwellis compare to Tenon Medical?

Does the media prefer NUWE or TNON?

Is NUWE or TNON more profitable?

Do analysts recommend NUWE or TNON?

Do insiders & institutionals believe in NUWE or TNON?

Which has better earnings & valuation, NUWE or TNON?

Which has more volatility and risk, NUWE or TNON?

Summary

How does Nuwellis compare to Intelligent Bio Solutions?

Do analysts rate NUWE or INBS?

Is NUWE or INBS more profitable?

Which has stronger earnings and valuation, NUWE or INBS?

Which has more volatility and risk, NUWE or INBS?

Do insiders and institutionals hold more shares of NUWE or INBS?

Does the media favor NUWE or INBS?

Summary

How does Nuwellis compare to Beyond Air?

Is XAIR or NUWE more profitable?

Do institutionals & insiders hold more shares of XAIR or NUWE?

Do analysts rate XAIR or NUWE?

Which has better valuation and earnings, XAIR or NUWE?

Does the media favor XAIR or NUWE?

Which has more risk & volatility, XAIR or NUWE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools